2023 Annual Meeting | C45 - The Landmark Carotid Stenosis Trials Are Obsolete

Date Sunday 04/23/23

Time 08:00 AM - 09:00 AM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Randolph S. Marshall, MD, F�鶹��ýӳ��

Topic(s) Cerebrovascular Disease and Interventional Neurology

Learning Objectives Participants should be able to identify advances in medical therapy that have altered outcomes in management of carotid atherosclerosis; explain why cognitition may be an important alternative outcome in patients with carotid artery stenosis; and assess the pros and cons of trans-carotid arterial revascularization for patient outcomes.

CME Available 1.00 CME credit

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic, Audience Participation, Other

Event Timeline
08:00 AM - 09:05 AM EST	Speaker	Introduction Randolph S. Marshall, MD, F�鶹��ýӳ��
08:05 AM - 08:20 AM EST	Speaker	Advances in Medical Therapy and New Trial Data Seemant Chaturvedi, MD, FAHA, F�鶹��ýӳ��
08:20 AM - 08:35 AM EST	Speaker	Cognition as an Alternative Outcome for Carotid Revascularization Randolph S. Marshall, MD, F�鶹��ýӳ��
08:35 AM - 08:45 AM EST	Speaker	Trans-Carotid Artery Revascularization: Pro Caitlin Hicks, MD, MS, FACS
08:45 AM - 08:55 AM EST	Speaker	Trans-Carotid Artery Revascularization: Con William Gray, MD
08:55 AM - 09:00 AM EST	Closing Remarks	Audience Survey and Conclusions Seemant Chaturvedi, MD, FAHA, F�鶹��ýӳ��

Faculty Disclosures
Randolph S. Marshall, MD, F�鶹��ýӳ��	The institution of Dr. Marshall has received research support from NIH. Dr. Marshall has received publishing royalties from a publication relating to health care.
Seemant Chaturvedi, MD, FAHA, F�鶹��ýӳ��	Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Chaturvedi has received research support from NINDS.
William Gray, MD	William Gray, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. William Gray, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. William Gray, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Phillips. William Gray, MD has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Gore.
Caitlin Hicks, MD, MS, FACS	Dr. Hicks has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Silk Road Medical LLC. Dr. Hicks has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cook Medical LLC. Dr. Hicks has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for W.L. Gore. Dr. Hicks has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier.